PD Dr. Hans Jürgen Rech

Einrichtungen, die zum Universitätsklinikum Erlangen gehören Medizinische Fakultät Department of Medicine 3 – Rheumatology and Immunology

Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis (2018) Neumann A, Haschka J, Kleyer A, Schuster L, Englbrecht M, Berlin A, Figueiredo CP, et al. Journal article Agonistic Autoantibodies to the β2-Adrenergic Receptor Involved in the Pathogenesis of Open-Angle Glaucoma (2018) Juenemann A, Hohberger B, Rech J, Sheriff A, Fu Q, Schlötzer-Schrehardt U, Voll RE, et al. Journal article A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints, the gut and the skin (2018) Simon D, Kleyer A, Englbrecht M, Stemmler F, Simon C, Berlin A, Kocijan R, et al. Journal article Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study (2018) Guilhon de Araujo E, Englbrecht M, Höpken S, Finzel S, Kampylafka E, Kleyer A, Bayat S, et al. Journal article Biomechanical properties of bone are impaired in patients with ACPA-positive rheumatoid arthritis and associated with the occurrence of fractures (2018) Stemmler F, Simon D, Liphardt AM, Englbrecht M, Rech J, Hueber A, Engelke K, et al. Journal article Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis (2018) Soare A, Weber S, Maul L, Rauber S, Gheorghiu AM, Luber M, Houssni I, et al. Journal article Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting (2018) Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll RE, et al. Journal article SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL (2017) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL (2017) Hall S, Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Geusens P, et al. Conference contribution Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1 (2017) Rech J, Reinhardt M, Kavanaugh A, Geusens P, Mpofu S Conference contribution